問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2394Cases

2015-05-01 - 2020-06-11

Phase II

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
5Sites

Terminated5Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of Orthopedics

2016-03-14 - 2017-09-07

Phase III

A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection (MAGELLAN-2)

  • Condition/Disease

    Post-Liver or Post-Renal Transplant Subjects with Chronic Hepatitis C Virus Genotype 1 – 6 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
2Sites

Terminated2Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2015-10-26 - 2017-05-30

Phase III

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 1 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
9Sites

Terminated8Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

2015-09-16 - 2017-06-30

Phase III

An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Condition/Disease

    Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

  • Test Drug

    ABT-450/Ritonavir/ABT-267, ABT-333, Ribavirin

Participate Sites
6Sites

Terminated5Sites

朱啟仁
Taipei Veterans General Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2018-03-01 - 2020-06-16

Phase II

Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    ABT-165

Participate Sites
3Sites

Terminated3Sites

2015-10-20 - 2017-05-30

Phase III

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

  • Condition/Disease

    Chronic Hepatitis C Virus Genotype 2 Infection

  • Test Drug

    ABT-493/ABT-530

Participate Sites
7Sites

Terminated4Sites

Study ended1Sites

彭成元
China Medical University Hospital

Digestive System Department

彭成元
China Medical University Hospital-Taipei

未分科

2017-04-01 - 2019-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

2016-10-10 - 2022-08-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis.

  • Condition/Disease

    Ulcerative colitis

  • Test Drug

    Upadacitinib(ABT-494)

Participate Sites
8Sites

Terminated6Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

2016-12-01 - 2019-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Venetoclax (ABT-199)

Participate Sites
6Sites

Terminated5Sites

蕭樑材
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-05-15 - 2020-04-09

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Rovalpituzumab Tesirine(Rova-T)

Participate Sites
9Sites

Terminated8Sites

洪仁宇
Kaohsiung Municipal Gangshan Hospital

未分科

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 136 137 138 139 140 240
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB